Blueprint Medicines (BPMC) Misses Q4 EPS by 9c ; Offers Guidance

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.79), $0.09 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $144.1 million versus the consensus estimate of $146.14 million.

GUIDANCE:

Blueprint Medicines sees FY2025 revenue of $680-710 million, versus the consensus of $726.2 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• Rambus launches DDR5 9600 server RDIMM chipset for AI workloads